| Significant Contribution |
1. Shweta Saraswat, Meenakshi Chaudhary, and Deepak Sehgal. Hepatitis E Virus Cysteine Protease has Papain Like Properties Validated by in silico Modeling and Cell-Free Inhibition Assays. Front Cell Infect Microbiol. 2019; 9: 478. (IF 4.123)
2. Shweta Saraswat, Athmaram TN, Manmohan Parida, Ankita Agarwal, Amrita Saha, Paban Kumar Dash. Expression and characterization of yeast derived Chikungunya virus like particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate. PLoS Negl Trop Dis. 2016;10:e0004782. (IF 3.948)
3. Shweta Saraswat, Athmaram Tn. A two step purification strategy for Chikungunya virions purification using sucrose buoyant density gradient separation. J Virol Res. 2013;2 :18-21. (IF 1.8)
4. Parida M, Dash PK, Kumar JS, Joshi G, Tandel K, Sharma S, Srivastava A, Agarwal A, Saha A, Saraswat S, Karothia D, Malviya V. Emergence of influenza A (H1N1) pdm09 Geno group 6B and drug resistant virus, India, January to May 2015. Euro Surveill. 2016;21(5):6-11. (IF 7.1)
5. Bhavna Sikarwar, Pushpendra K. Sharma, Shweta Saraswat, T. N. Athmaram, Mannan Boopathi, Beer Singh, Yogesh K. Jaiswal. Surface Plasmon Resonance Immunosensor for Recombinant H1N1 Protein. Plasmonics 2015;10:77-85 (IF 2.36)
6. T.N. Athmaram, Shweta Saraswat, Bhavna Sikarwar, Shailendra Kumar Verma, Anil K. Singh and M. Boopathi. Characterization of pandemic influenza A (H1N1) virus hemagglutinin specific polyclonal antibodies for biosensor applications. J Med. Virol. 2014;86:363-371 (IF 2.73)
7. T N Athmaram, Anil Kumar Singh, Shweta Saraswat, Saurabh Srivastava, Princi Misra, M Kameswara Rao, N Gopalan, P V L Rao. A simple Pichia pastoris fermentation and downstream processing strategy for making recombinant pandemic Swine Origin Influenza A virus Hemagglutinin protein. J Ind Microbiol Biotechnol 2013;40:245-255(IF 3.79)
8. T N Athmaram, Shweta Saraswat, Anil Kumar Singh, M Kameswara Rao, N Gopalan, V V S Suryanarayana, P V L Rao. Influence of copy number on the expression levels of pandemic influenza hemagglutinin recombinant protein in methylotrophic yeast Pichia pastoris. Virus Genes 2012; 8569 (IF 2.58)
9. T N Athmaram, Shweta Saraswat, Princi Misra, Saurabh Shrivastava, Anil K Singh, Shailendra K Verma, N Gopalan,Prativa K Behara, P V L Rao. Optimization of Dengue-3 recombinant NS1 protein expression in E. coli and in vitro refolding for diagnostic applications. Virus Genes 2012; 46(2) (IF 2.58)
10. TN Athmaram, Shweta Saraswat, SR Santhosh, Anil Kumar Singh,, VVS Suryanarayana, Raj Priya, N Gopalan, Manmohan Parida, PV Lakshmana Rao, and R Vijayaraghavan. Yeast expressed recombinant Hemagglutinin protein of Novel H1N1 elicits neutralising antibodies in rabbits and mice Virology Journal 2011; 8:524 (IF 3.35)
|
| Bio |
• October 2019 to October 2020: Scientist, in THSTI, Faridabad on project “Translational Research Consortium for establishing platform Technologies to support Prophylactic and Therapeutic strategies for Dengue- Discovery to proof-of-Conceptâ€. Virus isolation has been done using dengue infected serum samples. High tittered DENV of different serotype has been isolated, sequenced and amplified for bio-repository. Optimization of PRNT assays with different serotype of DENV has been done. These optimized parameters have been used for PRNT assay of dengue infected patient serum with all four DENV. CHIKV. Development of high titer DENV for mice experiment. Also involved in to check antiviral efficacy of different anti viral compounds against Dengue and other flaviviruses in vitro and in vivo in AG129 mice.
• DST-NPDF: January 2017 to September 2019: National Post Doctoral Fellow, working in Shiv Nadar University, Greater noida on project “Mapping of cleavage site of HEV ORF1 expressed using Baculovirus expression systemâ€. HEV-protease was expressed in insect cells and purified in native condition using affinity chromatography. The activity of this enzyme was checked using gelatin zymography, polyprotein digestion and Casein based assay. Further the enzyme kinetics of this enzyme was determined using FTC-casein based assay. its 3D structure was modeled using Insilco approach and docked against various protease inhibitors. E64 was found to inhibit its activity more than 95 % this was also validated through docking and protease inhibition assay. Through this analysis HEV-protease was found to be a cysteine protease inhibitor. Simultaneously 186kDa ORF1 plolyprotein was expressed and its cleavage was determined after digestion with HEV-protease. Digested product was loaded on SDS-PAGE and the presence of all the non structural enzymes cleaved after digestion of ORF1 was confirmed via epitope specific antibody of HEV raised against each enzyme.
• August 2010 to July 2016: Doctoral Research Fellow, Virology Division Defence Research & Development Establishment, Gwalior, India.
In the last six years, my research work has involved the studies related to vaccine against Chikungunya virus, pandemic Swine Flu H1N1 virus, and Dengue virus at BSL3+ Laboratory. We isolate and up scaled the virus to 2 liter culture. This virus was characterized by employing complete genome sequencing, molecular, biochemical and phylogeny tools. Apart from isolation and characterization of virus, vaccine strategies were developed using various eukaryotic expression system and their protective efficacies were evaluated. We expressed CHIK-VLPs, HA and NA of H1N1 and NS1 protein of Dengue Virus. Bioprocessing of CHIK-VLPs and HA protein have been done in 120 liters Bioreactor, for vaccine production, where as upscaling of NA and Dengue NS1 have also been done in Pilot scale Fermenter for antigen development. We also have developed diagnostic immunoassays for Dengue, Chikungunya and H1N1 virus.
• January 2009 to August 2010: JRF, Bioprocess Scale-up facility Defence Research & Development Establishment, Gwalior, on project entitled “Bioprocessing of Chikungunya E2 proteinâ€. Expression and upscaling of Chikungunya E2 protein has been done in Fed batch fermenter and this protein was purified by AKTA prime.
|
